Constitutive expression of calreticulin in osteoblasts inhibits mineralization.
Recent studies have shown that the multifunctional protein calreticulin can localize to the cell nucleus and regulate gene transcription via its ability to bind a protein motif in the DNA-binding domain of nuclear hormone receptors. A number of known modulators of bone cell function, including vitamin D, act through this receptor family, suggesting that calreticulin may regulate their action in bone cells. We have used a gain-of-function strategy to examine this putative role of calreticulin in MC3T3-E1 osteoblastic cells. Purified calreticulin inhibited the binding of the vitamin D receptor to characterized vitamin D response elements in gel retardation assays. This inhibition was due to direct protein-protein interactions between the vitamin D receptor and calreticulin. Expression of calreticulin transcripts declined during MC3T3-E1 osteoblastic differentiation. MC3T3-E1 cells were transfected with calreticulin expression vectors; stably transfected cell lines overexpressing recombinant calreticulin were established and assayed for vitamin D-induced gene expression and the capacity to mineralize. Constitutive calreticulin expression inhibited basal and vitamin D-induced expression of the osteocalcin gene, whereas osteopontin gene expression was unaffected. This pattern mimicked the gene expression pattern observed in parental cells before down-regulation of endogenous calreticulin expression. In long-term cultures of parental or vector-transfected cells, 1 alpha,25-dihydroxyvitamin D3 (1,25[OH]2D3) induced a two- to threefold stimulation of 45Ca accumulation into the matrix layer. Constitutive expression of calreticulin inhibited the 1,25(OH)2D3-induced 45Ca accumulation. This result correlated with the complete absence of mineralization nodules in long-term cultures of calreticulin-transfected cells. These data suggest that calreticulin can regulate bone cell function by interacting with specific nuclear hormone receptor-mediated pathways.
St-Arnaud
R
R
Genetics Unit, Shriners Hospital, Montréal, Québec, Canada.
Prud'homme
J
J
Leung-Hagesteijn
C
C
Dedhar
S
S
D000595:Amino Acid Sequence; D002113:Calcification, Physiologic / Q000502:physiology*; D002135:Calcium-Binding Proteins / Q000235:genetics / Q000502:physiology*; D037282:Calreticulin; D002454:Cell Differentiation; D002460:Cell Line; D005786:Gene Expression Regulation; D008969:Molecular Sequence Data; D010006:Osteoblasts / Q000502:physiology*; D015675:Osteocalcin / Q000235:genetics / Q000378:metabolism; D053495:Osteopontin; D011485:Protein Binding; D018167:Receptors, Calcitriol / Q000378:metabolism; D018168:Receptors, Retinoic Acid / Q000378:metabolism; D011993:Recombinant Fusion Proteins / Q000378:metabolism; D047488:Retinoid X Receptors; D012261:Ribonucleoproteins / Q000235:genetics / Q000502:physiology*; D012795:Sialoglycoproteins / Q000235:genetics / Q000378:metabolism; D014157:Transcription Factors / Q000378:metabolism; D014809:Vitamin D-Binding Protein / Q000378:metabolism
D002135:Calcium-Binding Proteins; D037282:Calreticulin; D018167:Receptors, Calcitriol; D018168:Receptors, Retinoic Acid; D011993:Recombinant Fusion Proteins; D047488:Retinoid X Receptors; D012261:Ribonucleoproteins; D012795:Sialoglycoproteins; D014157:Transcription Factors; D014809:Vitamin D-Binding Protein; D015675:Osteocalcin; D053495:Osteopontin